Rheumatoid Arthritis

Top Story

Phase 3 data confirms safety, efficacy of filgotinib for RA

Phase 3 data confirms safety, efficacy of filgotinib for RA
November 20, 2018
In the Journals

Adherence, persistence low in veterans with RA who escalate to triple therapy

November 19, 2018
Treatment adherence and persistence rates remain relatively low among veterans with rheumatoid arthritis who escalate from methotrexate to triple therapy with…
In the Journals

Few rheumatic adverse events from immune checkpoint inhibitors require discontinuation

November 15, 2018
Researchers found that the most prevalent adverse effect linked to immune checkpoint inhibitors was inflammatory arthritis, and although most patients received long…
Meeting News

All gains in infliximab biosimilar use have gone to Inflectra

November 13, 2018
CHICAGO — Researchers have observed a “modest uptake” in the use of biosimilars for infliximab in the past 18 months, although all such gains are among…
More Headlines »

Addressing Common Patient Concerns Regarding Biosimilars

This activity is supported by an educational grant from Pfizer, Inc.

As more biosimilars are approved for use in the United States, greater emphasis is needed on educating patients about…
More »
Meeting News

VIDEO: Cimzia data provides ‘reassuring’ pregnancy outcomes for rheumatic disease, IBD

June 16, 2018
More »

AWIR 2nd Annual Immunology Bootcamp Part 3: Signal Transduction and Biosimilars

This activity is supported by educational grants from AbbVie, Inc.; Amgen; Bristol-Myers Squibb; Pfizer, Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.

Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, psoriatic arthritis, vasculitis, and axial…
More »